Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial

PloS One
Ruben N EppingaRobin P F Dullaart

Abstract

Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the context of impaired glucose tolerance, but its effects in the setting of acute myocardial infarction (MI) are unknown. We determined whether metformin administration affects lipoprotein subfractions 4 months after ST-segment elevation MI (STEMI). Second, we assessed associations of lipoprotein subfractions with left ventricular ejection fraction (LVEF) and infarct size 4 months after STEMI. 371 participants without known diabetes participating in the GIPS-III trial, a placebo controlled, double-blind randomized trial studying the effect of metformin (500 mg bid) during 4 months after primary percutaneous coronary intervention for STEMI were included of whom 317 completed follow-up (clinicaltrial.gov Identifier: NCT01217307). Lipoprotein subfractions were measured using nuclear magnetic resonance spectroscopy at presentation, 24 hours and 4 months after STEMI. (Apo)lipoprotein measures were obtained during acute STEMI and 4 months post-STEMI. LVEF and infarct size were measured by cardiac magnetic resonance imaging. Metformin treatment slightly decreased LDL cholesterol levels (adjusted P = 0.01), whereas apoB remained unchanged. Large LDL...Continue Reading

Associated Clinical Trials

References

Jun 1, 1978·European Journal of Clinical Investigation·P AvogaroG Caturelli
Jul 22, 1998·Arteriosclerosis, Thrombosis, and Vascular Biology·D S FreedmanJ A Walker
Nov 18, 2006·Clinics in Laboratory Medicine·Elias J JeyarajahJames D Otvos
Nov 12, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Aug 13, 2010·European Journal of Clinical Investigation·Benoit J ArsenaultS Matthijs Boekholdt
Jan 14, 2011·The New England Journal of Medicine·Amit V KheraDaniel J Rader
Mar 12, 2011·Journal of Clinical Lipidology·James D OtvosDavid C Goff
Oct 20, 2011·Circulation. Cardiovascular Genetics·Michael P BrunnerL Kristin Newby
Mar 27, 2012·European Radiology·Dennis T L WongStephen G Worthley
Apr 28, 2012·Circulation·Sarah ParishUNKNOWN Heart Protection Study Collaborative Group
Aug 28, 2013·The Journal of Clinical Endocrinology and Metabolism·R GoldbergE Barrett-Connor
Feb 4, 2014·International Journal of Cardiology·Rafael SanjuanJuan Sanchis
Mar 13, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Robin P F DullaartUwe J F Tietge
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·David PreissNaveed Sattar
Apr 2, 2014·JAMA : the Journal of the American Medical Association·Chris P H LexisUNKNOWN GIPS-III Investigators
May 2, 2014·European Heart Journal·Jean-Claude TardifUNKNOWN Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators
Jun 7, 2014·Circulation Research·Robert S RosensonDaniel J Rader
Dec 3, 2014·The American Journal of Cardiology·Masashi FujinoHisao Ogawa

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear magnetic resonance
coronary artery bypass
NMR
sandwich immunoassay

Clinical Trials Mentioned

NCT01217307

Software Mentioned

corrplot
R

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.